Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have received a consensus rating of “Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $23.67.

Several analysts recently issued reports on ACRV shares. KeyCorp started coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald initiated coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company.

Institutional Trading of Acrivon Therapeutics

Several large investors have recently modified their holdings of ACRV. Acorn Capital Advisors LLC bought a new position in shares of Acrivon Therapeutics during the fourth quarter worth about $2,440,000. State Street Corp lifted its position in shares of Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the last quarter. Northern Trust Corp lifted its position in shares of Acrivon Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 117,323 shares of the company’s stock worth $706,000 after purchasing an additional 11,925 shares during the last quarter. Exome Asset Management LLC bought a new position in shares of Acrivon Therapeutics during the third quarter worth about $817,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Acrivon Therapeutics by 29.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after purchasing an additional 23,535 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Trading Up 7.3 %

Shares of NASDAQ ACRV opened at $5.44 on Tuesday. Acrivon Therapeutics has a 12-month low of $4.69 and a 12-month high of $11.90. The company has a market cap of $169.38 million, a P/E ratio of -2.01 and a beta of 0.85. The stock has a fifty day moving average price of $5.62 and a 200 day moving average price of $6.82.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.